-
Broken String Biosciences and BioLizard to Develop AI for Faster, Safer Gene Editing
Share BOSTON & CHICAGO & CAMBRIDGE, England–(BUSINESS WIRE)–Broken String Biosciences, a leader in advancing gene editing safety, and BioLizard, an expert in scientific data analytics and AI, today announced the development of SafeGuide, an AI tool for selecting safer, better guide RNAs (gRNA), the gene editing element that tells tools like CRISPR where to repair…
-
AI Meets Gene Editing: the Path to Plug-and-Play Drug Development
AI is no panacea, but it can have a role in turning artisanal, trial-and-error drug development into a rapid, cost-effective, data-driven process. By Felix Dobbs on July 10, 2025 8:58 am via MedCity News A generation ago, writing a piece like this about using artificial intelligence to develop genome-editing medicines would have sounded like a Star Trek plotline. But…
-
Broken String Biosciences Launches Catalyst Program to Shorten Gene Editing Therapy Development by Months
BOSTON, MA and Cambridge, UK, February 6, 2025 – Broken String Biosciences (“Broken String”), a leader in advancing gene editing safety, today opened its Catalyst Early Access Program (EAP) for developers of gene-edited therapies that allow for the detection of on- and off-target edits at high resolution, in days, in their own labs. The program…
-
Broken String Biosciences appoints Laurence Reid and Brad Crutchfield to its Board of Directors
Cambridge, UK, 23 September 2024: Broken String Biosciences (“Broken String”), a genomics company enabling development of the next generation of more precise, safe, and effective cell and gene therapies, today announced the appointments of Laurence Reid, PhD, as Chairman, and Brad Crutchfield as Non-Executive Director (NED) of its Board of Directors. Bringing extensive commercial and leadership expertise to the Board, Laurence…
-
Broken String Biosciences appoints Steve Becker as Chief Commercial Officer
Appointment brings extensive experience to lead commercial operations and accelerate growth in key global markets Cambridge, UK, 24 July 2024: Broken String Biosciences (“Broken String”), a genomics company driving development of the next generation of more precise, safe, and effective cell and gene therapies, today announced it has appointed Steve Becker as Chief Commercial Officer. An experienced global life sciences executive,…
-
Broken String Biosciences joins Campus
Cell & gene therapies based on genome editing technologies such as CRISPR-Cas9 are positioned to become a new generation of transformative therapeutics, with the ability to correct disease at the genetic level. Because they directly alter our DNA and have the propensity to go ‘off-target’, assessing whether these therapies are safe for patients is extremely…
-
Genomics company Broken String Biosciences expands presence within the Cambridge cluster with new laboratory at Chesterford Research Park
Chesterford Research Park is delighted to welcome Broken String Biosciences to the Park’s eminent Science Village. Aiming to develop safer cell and gene therapies by assessing the stability of the genome, Broken String Biosciences is leveraging novel genomic sequencing approaches to build a technology platform that will drive the development of CRISPR cell and gene therapies that…
